Asia-Pacific Companion Diagnostics Market: Focus on Application, End User, Technology, and Country - Analysis and Forecast, 2023-2033
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
This report will be delivered in 7-10 working days.Introduction to Asia-Pacific Companion Diagnostics Market
The Asia-Pacific companion diagnostics market was valued at $733.7 million in 2023 and is expected to reach $2,849.7 million by 2033, growing at a CAGR of 14.53% between 2023 and 2033. The Asia-Pacific (APAC) companion diagnostics market is growing as a result of increased approvals for companion diagnostic tools, improvements in biomedical imaging, and the rising incidence of cancer. These are the main causes of the increasing use of precision medicine and companion diagnostics in APAC's individualized cancer treatment.
Market Introduction
The market for companion diagnostics in Asia-Pacific (APAC) is expected to develop significantly due to the increased need for personalized therapy and the rising prevalence of chronic diseases, especially cancer. In order to provide more specialized and efficient treatment options, companion diagnostics are crucial instruments that assist in identifying patients who are most likely to benefit from particular medicines. Companion diagnostics are becoming more and more important as the region sees an increase in cancer incidence and a greater focus on precision treatment.
The market is also being driven ahead by technological developments in assay development and biomarker discovery. The development of customized treatments is made easier by the discovery of biomarkers linked to a variety of diseases thanks to advancements in genomic and molecular testing technology. Furthermore, encouraging legal frameworks, more funding for research and development by pharmaceutical companies are contributing to the market's expansion.
Leading the way in the adoption of companion diagnostics are nations like China, India, and Japan, where biopharmaceutical businesses and diagnostic companies have partnered in large numbers. The APAC companion diagnostic market is expected to increase as patients and healthcare professionals become more aware of the advantages of personalized medicine, providing substantial potential for all parties involved in the healthcare ecosystem.
Market Segmentation
Segmentation 1: by Technology
Product/Innovation Strategy: The Asia-Pacific companion diagnostics market has been segmented based on various categories, such as technology, application, end user, and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Competitive Strategy: The Asia-Pacific companion diagnostics market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Asia-Pacific companion diagnostics market analyzed and profiled in the study involve established players that offer various kinds of products and services.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are:
This report will be delivered in 7-10 working days.Introduction to Asia-Pacific Companion Diagnostics Market
The Asia-Pacific companion diagnostics market was valued at $733.7 million in 2023 and is expected to reach $2,849.7 million by 2033, growing at a CAGR of 14.53% between 2023 and 2033. The Asia-Pacific (APAC) companion diagnostics market is growing as a result of increased approvals for companion diagnostic tools, improvements in biomedical imaging, and the rising incidence of cancer. These are the main causes of the increasing use of precision medicine and companion diagnostics in APAC's individualized cancer treatment.
Market Introduction
The market for companion diagnostics in Asia-Pacific (APAC) is expected to develop significantly due to the increased need for personalized therapy and the rising prevalence of chronic diseases, especially cancer. In order to provide more specialized and efficient treatment options, companion diagnostics are crucial instruments that assist in identifying patients who are most likely to benefit from particular medicines. Companion diagnostics are becoming more and more important as the region sees an increase in cancer incidence and a greater focus on precision treatment.
The market is also being driven ahead by technological developments in assay development and biomarker discovery. The development of customized treatments is made easier by the discovery of biomarkers linked to a variety of diseases thanks to advancements in genomic and molecular testing technology. Furthermore, encouraging legal frameworks, more funding for research and development by pharmaceutical companies are contributing to the market's expansion.
Leading the way in the adoption of companion diagnostics are nations like China, India, and Japan, where biopharmaceutical businesses and diagnostic companies have partnered in large numbers. The APAC companion diagnostic market is expected to increase as patients and healthcare professionals become more aware of the advantages of personalized medicine, providing substantial potential for all parties involved in the healthcare ecosystem.
Market Segmentation
Segmentation 1: by Technology
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- In-Situ Hybridization (ISH)
- Next-Generation Sequencing (NGS)
- Others
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Stomach Cancer
- Melanoma
- Others
- Pharmaceutical and Biotechnology Companies
- Reference Laboratories and Hospitals
- Others
- Japan
- India
- China
- South Korea
- Australia
- Rest-of-Asia-Pacific
Product/Innovation Strategy: The Asia-Pacific companion diagnostics market has been segmented based on various categories, such as technology, application, end user, and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Competitive Strategy: The Asia-Pacific companion diagnostics market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Asia-Pacific companion diagnostics market analyzed and profiled in the study involve established players that offer various kinds of products and services.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are:
- Amoy Diagnostics Co., Ltd.
- Novogene Co, Ltd.
- Sysmex Corporation
Executive Summary
Scope and Definition
1 MARKETS
1.1 Trends: Current and Future Impact Assessment
1.1.1 Companion Diagnostics Market Trend Analysis
1.1.2 Implementation of Liquid Biopsy-Based Companion Diagnostics
1.1.3 Combining Artificial Intelligence and Companion Diagnostics
1.2 Supply Chain Overview
1.2.1 Value Chain Analysis
1.3 Research and Development Review
1.3.1 Patent Filing Trend (by Country, Year)
1.4 Regulatory Landscape
1.4.1 Legal Requirements and Framework by the FDA
1.4.2 Legal Requirements and Framework by the MHLW
1.5 CDx from a Historical Perspective
1.6 Constituents for Companion Diagnostics (CDx) Development
1.7 Companion Diagnostics (CDx): Future Potential
1.8 Market Dynamics Overview
1.8.1 Market Drivers
1.8.1.1 Rising Prevalence of Cancer Cases
1.8.1.2 Increasing Product Approvals in the Field of Companion Diagnostics
1.8.1.3 Advancing Biomedical Imaging as the Driving Force for Precision Medicine's Companion Diagnostics
1.8.2 Market Restraints
1.8.2.1 Uncertain Reimbursement Scenario
1.8.2.2 Stringent Regulatory Approval Processes
1.8.3 Market Opportunities
1.8.3.1 Progress in Companion Diagnostics Driven by Continuous Development and Technological Advancements
1.8.3.2 Introduction of Epigenomics-Based Companion Diagnostics
2 REGIONS
2.1 Regional Summary
2.2 Drivers and Restraints
2.3 Asia-Pacific
2.3.1 Regional Overview
2.3.2 Driving Factors for Market Growth
2.3.3 Factors Challenging the Market
2.3.4 Application
2.3.5 Product
2.3.6 China
2.3.7 Application
2.3.8 Product
2.3.9 India
2.3.10 Application
2.3.11 Product
2.3.12 Australia
2.3.13 Application
2.3.14 Product
2.3.15 Japan
2.3.16 Application
2.3.17 Product
2.3.18 South Korea
2.3.19 Application
2.3.20 Product
2.3.21 Rest-of-Asia-Pacific
2.3.22 Application
2.3.23 Product
3 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES
3.1 Next Frontiers…..
3.2 Geographic Assessment
3.2.1 Amoy Diagnostics Co., Ltd.
3.2.1.1 Overview
3.2.1.2 Top Products/Product Portfolio
3.2.1.3 Top Competitors
3.2.1.4 Target Customers
3.2.1.5 Key Personnel
3.2.1.6 Analyst View
3.2.2 Novogene Co, Ltd.
3.2.2.1 Overview
3.2.2.2 Top Products/Product Portfolio
3.2.2.3 Top Competitors
3.2.2.4 Target Customers
3.2.2.5 Key Personnel
3.2.2.6 Analyst View
3.2.3 Sysmex Corporation
3.2.3.1 Overview
3.2.3.2 Top Products/Product Portfolio
3.2.3.3 Top Competitors
3.2.3.4 Target Customers
3.2.3.5 Key Personnel
3.2.3.6 Analyst View
4 RESEARCH METHODOLOGY
4.1 Data Sources
4.1.1 Primary Data Sources
4.1.2 Secondary Data Sources
4.1.3 Data Triangulation
4.2 Market Estimation and Forecast
Scope and Definition
1 MARKETS
1.1 Trends: Current and Future Impact Assessment
1.1.1 Companion Diagnostics Market Trend Analysis
1.1.2 Implementation of Liquid Biopsy-Based Companion Diagnostics
1.1.3 Combining Artificial Intelligence and Companion Diagnostics
1.2 Supply Chain Overview
1.2.1 Value Chain Analysis
1.3 Research and Development Review
1.3.1 Patent Filing Trend (by Country, Year)
1.4 Regulatory Landscape
1.4.1 Legal Requirements and Framework by the FDA
1.4.2 Legal Requirements and Framework by the MHLW
1.5 CDx from a Historical Perspective
1.6 Constituents for Companion Diagnostics (CDx) Development
1.7 Companion Diagnostics (CDx): Future Potential
1.8 Market Dynamics Overview
1.8.1 Market Drivers
1.8.1.1 Rising Prevalence of Cancer Cases
1.8.1.2 Increasing Product Approvals in the Field of Companion Diagnostics
1.8.1.3 Advancing Biomedical Imaging as the Driving Force for Precision Medicine's Companion Diagnostics
1.8.2 Market Restraints
1.8.2.1 Uncertain Reimbursement Scenario
1.8.2.2 Stringent Regulatory Approval Processes
1.8.3 Market Opportunities
1.8.3.1 Progress in Companion Diagnostics Driven by Continuous Development and Technological Advancements
1.8.3.2 Introduction of Epigenomics-Based Companion Diagnostics
2 REGIONS
2.1 Regional Summary
2.2 Drivers and Restraints
2.3 Asia-Pacific
2.3.1 Regional Overview
2.3.2 Driving Factors for Market Growth
2.3.3 Factors Challenging the Market
2.3.4 Application
2.3.5 Product
2.3.6 China
2.3.7 Application
2.3.8 Product
2.3.9 India
2.3.10 Application
2.3.11 Product
2.3.12 Australia
2.3.13 Application
2.3.14 Product
2.3.15 Japan
2.3.16 Application
2.3.17 Product
2.3.18 South Korea
2.3.19 Application
2.3.20 Product
2.3.21 Rest-of-Asia-Pacific
2.3.22 Application
2.3.23 Product
3 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES
3.1 Next Frontiers…..
3.2 Geographic Assessment
3.2.1 Amoy Diagnostics Co., Ltd.
3.2.1.1 Overview
3.2.1.2 Top Products/Product Portfolio
3.2.1.3 Top Competitors
3.2.1.4 Target Customers
3.2.1.5 Key Personnel
3.2.1.6 Analyst View
3.2.2 Novogene Co, Ltd.
3.2.2.1 Overview
3.2.2.2 Top Products/Product Portfolio
3.2.2.3 Top Competitors
3.2.2.4 Target Customers
3.2.2.5 Key Personnel
3.2.2.6 Analyst View
3.2.3 Sysmex Corporation
3.2.3.1 Overview
3.2.3.2 Top Products/Product Portfolio
3.2.3.3 Top Competitors
3.2.3.4 Target Customers
3.2.3.5 Key Personnel
3.2.3.6 Analyst View
4 RESEARCH METHODOLOGY
4.1 Data Sources
4.1.1 Primary Data Sources
4.1.2 Secondary Data Sources
4.1.3 Data Triangulation
4.2 Market Estimation and Forecast
LIST OF FIGURES
Figure 1: Asia-Pacific Companion Diagnostics Market, $Million, 2023, 2026, and 2033
Figure 2: Asia-Pacific Companion Diagnostics Market (by Application), $Million, 2022, 2026, and 2033
Figure 3: Asia-Pacific Companion Diagnostics Market (by Technology), $Million, 2022, 2026, and 2033
Figure 4: Asia-Pacific Companion Diagnostics Market (by End User), $Million, 2022, 2026, and 2033
Figure 5: Key Industrial Developments in Companion Diagnostics Market, 2023
Figure 6: Key Aspects Related to Liquid Biopsy-Based Companion Diagnostics
Figure 7: Applications of Digital Diagnostics
Figure 8: Supply Chain and Risks within the Supply Chain
Figure 9: Companion Diagnostics Market (by Country), January 2021-December 2023
Figure 10: Companion Diagnostics (by Year), January 2021-December 2023
Figure 11: Evolution of Companion Diagnostics
Figure 12: Components Required to Develop Companion Diagnostics
Figure 13: Future Prospects of CDx
Figure 14: Impact Analysis of Market Navigating Factors, 2023-2033
Figure 15: Factors Impacting Reimbursement Scenario
Figure 16: Advancements in Companion Diagnostics
Figure 17: Future Outlook of Epigenomics
Figure 18: Asia-Pacific Companion Diagnostics Market, $Million, 2022-2033
Figure 19: China Companion Diagnostics Market, $Million, 2022-2033
Figure 20: India Companion Diagnostics Market, $Million, 2022-2033
Figure 21: Australia Companion Diagnostics Market, $Million, 2022-2033
Figure 22: Japan Companion Diagnostics Market, $Million, 2022-2033
Figure 23: South Korea Companion Diagnostics Market, $Million, 2022-2033
Figure 24: Rest-of-Asia-Pacific Companion Diagnostics Market, $Million, 2022-2033
Figure 25: Strategic Initiatives, 2021-2023
Figure 26: Share of Strategic Initiatives, 2021-2023
Figure 27: Data Triangulation
Figure 28: Top-Down and Bottom-Up Approach
Figure 29: Assumptions and Limitations
Figure 1: Asia-Pacific Companion Diagnostics Market, $Million, 2023, 2026, and 2033
Figure 2: Asia-Pacific Companion Diagnostics Market (by Application), $Million, 2022, 2026, and 2033
Figure 3: Asia-Pacific Companion Diagnostics Market (by Technology), $Million, 2022, 2026, and 2033
Figure 4: Asia-Pacific Companion Diagnostics Market (by End User), $Million, 2022, 2026, and 2033
Figure 5: Key Industrial Developments in Companion Diagnostics Market, 2023
Figure 6: Key Aspects Related to Liquid Biopsy-Based Companion Diagnostics
Figure 7: Applications of Digital Diagnostics
Figure 8: Supply Chain and Risks within the Supply Chain
Figure 9: Companion Diagnostics Market (by Country), January 2021-December 2023
Figure 10: Companion Diagnostics (by Year), January 2021-December 2023
Figure 11: Evolution of Companion Diagnostics
Figure 12: Components Required to Develop Companion Diagnostics
Figure 13: Future Prospects of CDx
Figure 14: Impact Analysis of Market Navigating Factors, 2023-2033
Figure 15: Factors Impacting Reimbursement Scenario
Figure 16: Advancements in Companion Diagnostics
Figure 17: Future Outlook of Epigenomics
Figure 18: Asia-Pacific Companion Diagnostics Market, $Million, 2022-2033
Figure 19: China Companion Diagnostics Market, $Million, 2022-2033
Figure 20: India Companion Diagnostics Market, $Million, 2022-2033
Figure 21: Australia Companion Diagnostics Market, $Million, 2022-2033
Figure 22: Japan Companion Diagnostics Market, $Million, 2022-2033
Figure 23: South Korea Companion Diagnostics Market, $Million, 2022-2033
Figure 24: Rest-of-Asia-Pacific Companion Diagnostics Market, $Million, 2022-2033
Figure 25: Strategic Initiatives, 2021-2023
Figure 26: Share of Strategic Initiatives, 2021-2023
Figure 27: Data Triangulation
Figure 28: Top-Down and Bottom-Up Approach
Figure 29: Assumptions and Limitations
LIST OF TABLES
Table 1: Market Snapshot
Table 2: Companion Diagnostics Market, Opportunities
Table 3: Some of FDA Approved Liquid Biopsy CDx Tests
Table 4: Cancer Cases Expected between 2020 and 2040
Table 5: Product Approvals in the Field of Companion Diagnostics
Table 6: Companion Diagnostics Preparation (by Region), $Million, 2022-2033
Table 7: Asia-Pacific Companion Diagnostics Market (by Application), $Million, 2022-2033
Table 8: Asia-Pacific Companion Diagnostics Market (by End User), $Million, 2022-2033
Table 9: Asia-Pacific Companion Diagnostics Market (by Technology), $Million, 2022-2033
Table 10: China Companion Diagnostics Market (by Application), $Million, 2022-2033
Table 11: China Companion Diagnostics Market (by End User), $Million, 2022-2033
Table 12: China Companion Diagnostics Market (by Technology), $Million, 2022-2033
Table 13: India Companion Diagnostics Market (by Application), $Million, 2022-2033
Table 14: India Companion Diagnostics Market (by End User), $Million, 2022-2033
Table 15: India Companion Diagnostics Market (by Technology), $Million, 2022-2033
Table 16: Australia Companion Diagnostics Market (by Application), $Million, 2022-2033
Table 17: Australia Companion Diagnostics Market (by End User), $Million, 2022-2033
Table 18: Australia Companion Diagnostics Market (by Technology), $Million, 2022-2033
Table 19: Japan Companion Diagnostics Market (by Application), $Million, 2022-2033
Table 20: Japan Companion Diagnostics Market (by End User), $Million, 2022-2033
Table 21: Japan Companion Diagnostics Market (by Technology), $Million, 2022-2033
Table 22: South Korea Companion Diagnostics Market (by Application), $Million, 2022-2033
Table 23: South Korea Companion Diagnostics Market (by End User), $Million, 2022-2033
Table 24: South Korea Companion Diagnostics Market (by Technology), $Million, 2022-2033
Table 25: Rest-of-Asia-Pacific Companion Diagnostics Market (by Application), $Million, 2022-2033
Table 26: Rest-of-Asia-Pacific Companion Diagnostics Market (by End User), $Million, 2022-2033
Table 27: Rest-of-Asia-Pacific Companion Diagnostics Market (by Technology), $Million, 2022-2033
Table 1: Market Snapshot
Table 2: Companion Diagnostics Market, Opportunities
Table 3: Some of FDA Approved Liquid Biopsy CDx Tests
Table 4: Cancer Cases Expected between 2020 and 2040
Table 5: Product Approvals in the Field of Companion Diagnostics
Table 6: Companion Diagnostics Preparation (by Region), $Million, 2022-2033
Table 7: Asia-Pacific Companion Diagnostics Market (by Application), $Million, 2022-2033
Table 8: Asia-Pacific Companion Diagnostics Market (by End User), $Million, 2022-2033
Table 9: Asia-Pacific Companion Diagnostics Market (by Technology), $Million, 2022-2033
Table 10: China Companion Diagnostics Market (by Application), $Million, 2022-2033
Table 11: China Companion Diagnostics Market (by End User), $Million, 2022-2033
Table 12: China Companion Diagnostics Market (by Technology), $Million, 2022-2033
Table 13: India Companion Diagnostics Market (by Application), $Million, 2022-2033
Table 14: India Companion Diagnostics Market (by End User), $Million, 2022-2033
Table 15: India Companion Diagnostics Market (by Technology), $Million, 2022-2033
Table 16: Australia Companion Diagnostics Market (by Application), $Million, 2022-2033
Table 17: Australia Companion Diagnostics Market (by End User), $Million, 2022-2033
Table 18: Australia Companion Diagnostics Market (by Technology), $Million, 2022-2033
Table 19: Japan Companion Diagnostics Market (by Application), $Million, 2022-2033
Table 20: Japan Companion Diagnostics Market (by End User), $Million, 2022-2033
Table 21: Japan Companion Diagnostics Market (by Technology), $Million, 2022-2033
Table 22: South Korea Companion Diagnostics Market (by Application), $Million, 2022-2033
Table 23: South Korea Companion Diagnostics Market (by End User), $Million, 2022-2033
Table 24: South Korea Companion Diagnostics Market (by Technology), $Million, 2022-2033
Table 25: Rest-of-Asia-Pacific Companion Diagnostics Market (by Application), $Million, 2022-2033
Table 26: Rest-of-Asia-Pacific Companion Diagnostics Market (by End User), $Million, 2022-2033
Table 27: Rest-of-Asia-Pacific Companion Diagnostics Market (by Technology), $Million, 2022-2033
